Session 5 has the same title folks...the other sessions including under "Unique Challenges In Emerging Immunotherapies." are still listed when in the live event schedule. The presentation is going to happen.
Tuesday, May 10, 2022
6:00 AM
6:00 AM - 7:40 AM PDT
Session 5: Unique Challenges in Emerging Immunotherapies
LIVE
Session Chair: George Zavoico, PhD, Cue Biopharma
9:00 AM
Welcome Remarks
Barbara Knappmeyer, PhD, The New York Academy of Sciences
Session 5: Unique Challenges in Emerging Immunotherapies
Session Chair: To be announced
9:10 AM
Immune Checkpoint Blockade in Glioblastoma
David Reardon, MD, Dana Farber Cancer Institute
9:40 AM
How Do CAR T Cells Kill Cancer?
Marcela V. Maus, MD, PhD, Massachusetts General Hospital, Harvard Medical School
10:10 AM
Immunotherapeutic Approaches to Glioblastoma Treatment
Vinay K. Puduvalli, MD, MD Anderson Cancer Center
Virtual session
Join session
8:10 AM
8:10 AM - 9:10 AM PDT
Session 6: Unique Challenges in Emerging Immunotherapies (Continued)
11:10 AM
Autologous Tumor Lysate-loaded Dendritic Cell Vaccination for Glioblastoma
Paul Mulholland, MBBS, MSc, PhD, FRCP, University College Hospital *
11:40 AM
Independent Drug Action in Immunotherapy: Implications for Drug Discovery and Precision Medicine
Peter Sorger, PhD, Harvard Medical School
Virtual session
Included session
9:10 AM
9:10 AM - 9:40 AM PDT
Session 7: Short Talks
12:10 PM
Targeting SIRPa as a Therapeutic Strategy For the Treatment of Breast Cancer Brain Metastasis
Jessica Mackert, PhD, Wake Forest School of Medicine
12:25 PM
Notch Orchestrates A Multifaceted Immune Evasion Program in Hepatocellular Carcinoma
Katherine Linblad, Icahn School of Medicine at Mount Sinai
Virtual session
Included session
11:10 AM
11:10 AM - 12:55 PM PDT
Session 8: Keynote & Session 9: Cytokines as Therapeutics
Session 8: Keynote
Session Chair: George Zavoico, PhD, CueBiopharma
2:10 PM
Cancer and the Immune System
Abul K. Abbas, MBBS, University of California San Francisco School of Medicine
Session 9: Cytokines as Therapeutics
Session Chair: George Zavoico, PhD, CueBiopharma
2:55 PM
Cell Type-Selective Targeting Improves Anti-Tumor Activity and Safety of Cytokines
Ivana Djuretic, PhD, Asher Biotherapeutics
3:25 PM
Expansion of Tumoral CD8 T Cells with a Targeted IL-15 Mutein
Robert C. Rickert, PhD, Pfizer
Featured session
Virtual session
Included session
12:55 PM
12:55 PM - 1:55 PM PDT
Session 10: Poster Session
3:55 PM
Poster Session
4:55 PM
Day 2 - Closing Remarks
Barbara Knappmeyer, PhD, The New York Academy of Sciences
Featured session
Included session
AI
